Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21268236 | 0.85 | CA12 (0.36) | KDM4ERECQLMAPTMAPK1LMNA | |
| SCHEMBL9682626 | 0.85 | TUBB4A (0.43) | MAPTMAPK1LMNAL3MBTL1RAB9A | |
| SCHEMBL21268325 | 0.82 | KDM4E (0.44) | KDM4ERECQLMAPK1L3MBTL1ALDH1A1 | |
| SCHEMBL2454340 | 0.81 | NQO1 (0.50) | KDM4EMAPTMAPK1LMNAL3MBTL1 | |
| SCHEMBL7688412 | 0.81 | NR5A1 (0.50) | MAPTLMNARAB9A | |
| SCHEMBL19435886 | 0.79 | KDM4E (0.37) | KDM4ERECQLMAPTMAOADYRK1A | |
| SCHEMBL14814084 | 0.78 | KDM4E (0.36) | KDM4ERECQLMAPTMAOADYRK1A | |
| SCHEMBL27852529 | 0.78 | MAPT (0.38) | KDM4ERECQLMAPTMAOADYRK1A | |
| SCHEMBL14237450 | 0.78 | PRKAB2 (0.36) | KDM4ERECQLMAPTMAOADYRK1A | |
| SCHEMBL105204 | 0.78 | CA1 (0.48) | KDM4ERECQLMAPTMAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10918640-B2 | Azetidine derivatives | VERNALIS (R&D) LTD. (GB) | 2021-02-16 | — | — | US | claimed |
| US-10383871-B2 | Azetidine derivatives | VERNALIS (R&D) LTD. (GB) | 2019-08-20 | — | — | US | claimed |
| US-20170196864-A1 | Azetidine Derivatives | VERNALIS DEVELOPMENT LIMITED (GB) | 2017-07-13 | — | — | US | claimed |
| US-9475800-B2 | Azetidine derivatives | VERNALIS (R&D) LTD. (GB) | 2016-10-25 | — | — | US | claimed |
| EP-2265578-B1 | AZETIDINE DERIVATIVES | VERNALIS R&D LTD (GB) | 2015-09-16 | — | — | EP | claimed |
| US-20150183769-A1 | Azetidine Derivatives | VERNALIS DEVELOPMENT LIMITED (GB) | 2015-07-02 | — | — | US | claimed |
| US-9006269-B2 | Azetidine derivatives | VERNALIS (R&D) LTD. (GB) | 2015-04-14 | — | — | US | claimed |
| US-20130331371-A1 | Azetidine Derivatives | VERNALIS (R&D) LTD. (GB) | 2013-12-12 | — | — | US | claimed |
| US-8450346-B2 | Azetidine derivatives as FAAH inhibitors | VERNALIS (R&D) LTD. (GB) | 2013-05-28 | — | — | US | claimed |
| US-20120028953-A1 | Azetidine Derivatives | VERNALIS (R&D) LTD. (GB) | 2012-02-02 | — | — | US | claimed |
| EP-2265578-A1 | AZETIDINE DERIVATIVES | Vernalis (R&D) Ltd. (GB) | 2010-12-29 | — | — | EP | claimed |
| WO-2009109743-A1 | AZETIDINE DERIVATIVES | VERNALIS (R&D) LTD. (GB) | 2009-09-11 | — | — | WO | claimed |
| US-10918640-B2 | Azetidine derivatives | VERNALIS (R&D) LTD. (GB) | 2021-02-16 | — | — | US | disclosed |
| US-10383871-B2 | Azetidine derivatives | VERNALIS (R&D) LTD. (GB) | 2019-08-20 | — | — | US | disclosed |
| US-20170196864-A1 | Azetidine Derivatives | VERNALIS DEVELOPMENT LIMITED (GB) | 2017-07-13 | — | — | US | disclosed |
| US-9475800-B2 | Azetidine derivatives | VERNALIS (R&D) LTD. (GB) | 2016-10-25 | — | — | US | disclosed |
| US-8450346-B2 | Azetidine derivatives as FAAH inhibitors | VERNALIS (R&D) LTD. (GB) | 2013-05-28 | — | — | US | disclosed |
| US-20120028953-A1 | Azetidine Derivatives | VERNALIS (R&D) LTD. (GB) | 2012-02-02 | — | — | US | disclosed |
| EP-2265578-A1 | AZETIDINE DERIVATIVES | Vernalis (R&D) Ltd. (GB) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009109743-A1 | AZETIDINE DERIVATIVES | VERNALIS (R&D) LTD. (GB) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10918640-B2 | Azetidine derivatives | FAAH2, FAAH, APEH | KDM4E 1262/4885RECQL 1373/4885MAPT 3245/4885 |
| US-20130331371-A1 | Azetidine Derivatives | FAAH2, FAAH, APEH | KDM4E 1151/4885RECQL 1362/4885MAPT 3263/4885 |
| US-20120028953-A1 | Azetidine Derivatives | FAAH2, FAAH, APEH | KDM4E 1288/4885RECQL 1390/4885MAPT 3158/4885 |
| US-20150183769-A1 | Azetidine Derivatives | FAAH2, FAAH, APEH | KDM4E 1151/4885RECQL 1362/4885MAPT 3263/4885 |
| US-20170196864-A1 | Azetidine Derivatives | FAAH2, FAAH, APEH | KDM4E 1262/4885RECQL 1373/4885MAPT 3245/4885 |
| US-10383871-B2 | Azetidine derivatives | FAAH2, FAAH, APEH | KDM4E 1262/4885RECQL 1373/4885MAPT 3245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.